Disc Medicine dives as FDA declines to approve rare disease drug

Disc Medicine's IRON.O shares down 28.4% at $51.3

Blood disease-focused biopharma says U.S. FDA has declined to approve Bitopertin, its rare genetic disorder treatment

Bitopertin has been under review for accelerated approval and as part of the Commissioner's National Priority Voucher pilot program

FDA indicated a need to see the results of the ongoing late-stage APOLLO study before making a decision - IRON

Topline data from APOLLO study expected in Q4

Including session losses, stock down roughly 41% YTD